CLEVELAND, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced its financial results for the second quarter of 2011. The Company is successfully developing a portfolio of clinical stage programs involving MultiStem®, a patented non-embryonic stem cell therapy that has shown promise in multiple areas of significant unmet clinical need, including treating cardiovascular disease, inflammatory and immune disorders, and neurological conditions.
